Core Viewpoint - A class action lawsuit has been filed against Baxter International Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al., No. 1:25-cv-12672 [3]. - Investors have until December 15, 2025, to request to lead the case [3]. Group 2: Product Issues - Baxter's Novum IQ Large Volume pump, a key growth driver, faced serious malfunctions after its launch in Canada, including under-infusion and over-infusion of medications [4][5]. - The company previously claimed that the Novum LVP had advanced safety features and that the Canadian rollout would help resolve any issues [5]. Group 3: Stock Impact - On July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, leading to a stock price drop of $6.29 per share, or over 22%, from $28.05 to $21.76 [6].

Core Viewpoint - A class action lawsuit has been filed against Baxter International Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al., No. 1:25-cv-12672 [3]. - Investors have until December 15, 2025, to request to be appointed to lead the case [3]. Group 2: Product Issues - Baxter's Novum IQ Large Volume pump, a key growth driver, faced serious malfunctions after its launch in Canada, including under-infusion and over-infusion of medications [4][5]. - The company previously claimed that the Novum LVP had advanced safety features and that the Canadian rollout would help resolve any issues, which was later alleged to be misleading [5]. Group 3: Stock Impact - Following the announcement on July 31, 2025, to pause shipments and installations of the Novum LVP, Baxter's stock price fell by $6.29 per share, a decline of over 22%, from $28.05 to $21.76 [6].

Core Viewpoint - A class action lawsuit has been filed against Baxter International Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al., No. 1:25-cv-12672 [3]. - Investors have until December 15, 2025, to request to be appointed to lead the case [3]. Group 2: Product Issues - Baxter's Novum IQ Large Volume pump, a key growth driver, faced serious malfunctions after its launch in Canada, including under-infusion and over-infusion of medications [4][5]. - The company previously claimed that the Novum LVP had advanced safety features and that the Canadian rollout would help resolve any issues [5]. Group 3: Stock Impact - Following the announcement on July 31, 2025, to pause shipments and installations of the Novum LVP, Baxter's stock price dropped by $6.29, or over 22%, from $28.05 to $21.76 per share [6].

Q2 2025 Performance Summary - Worldwide sales from continuing operations grew 4% on a reported basis and 1% on an operational basis[18] - Adjusted earnings per share from continuing operations totaled $0.59 per diluted share, increasing 28% as compared to the prior year period[18] - Gross Margin was 353%, with a year-over-year change of (300 bps)[20] - Operating Margin was 68%, with a year-over-year change of +20 bps[20] - Diluted EPS was $024, with a year-over-year change of +26%[20] H1 2025 Performance Summary - Sales were $54 billion, with a +5% Reported and +3% Operational[20] - Gross Margin was 341%, with a year-over-year change of (430 bps)[20] - Operating Margin was 46%, with a year-over-year change of (110 bps)[20] - Diluted EPS was $036, with a year-over-year change of +80%[20] - Adjusted Diluted EPS was $115, with a year-over-year change of +40%[20] Q3 & FY 2025 Outlook - Third-Quarter 2025 Sales Growth Reported (Continuing Operations) Guidance is 6% - 7%[60] - Third-Quarter 2025 Operational Sales Growth (Continuing Operations) Guidance is ~ 3% - 4%[60] - Third-Quarter 2025 Adjusted Diluted EPS Continuing Operations is $058 - $062[60] - Full-Year 2025 Sales Growth Reported (Continuing Operations) Guidance is 6% - 7%[62] - Full-Year 2025 Operational Sales Growth (Continuing Operations) Guidance is 3% - 4%[62] - Full-Year 2025 Adjusted Diluted EPS Continuing Operations is $242 - $252[62]